HAE Haemonetics Corporation Common Stock
关于 Haemonetics Corporation Common Stock 公司概况(来自维基百科)
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
阅读更多
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
Today, the company has expanded and has offices located in 16 countries. The company employs more than 1,800 people and markets its products in over 50 countries. Revenue is derived nearly equally from its three major markets -- Asia, Europe, and the Americas.
History
The company was founded in 1971. Haemonetics started out producing the containers and bags required for blood collection. The Latham Bowl was a disposable container that could automate the separation of blood by centrifugation. Through the 90's, the company added additional product lines and technologies. The company opened a manufacturing facility in Holbrook, Massachusetts in 1988.
In 1995 the company purchased the Intravenous Solutions manufacturing facility in Union, South Carolina.
Additional acquisitions grew the company and expanded its services. In the following years the company branched off to making the whole plasma collection station including the machine, supplies and software for plasma collection. These acquisitions included Edmonton-based Fifth Dimension (5D) Information Systems to gain entry into the blood and plasma software industry. Further acquisitions include Chicago-based Arryx in July 2006, Information Data Management, Inc. in January 2007, the acquisition of a division of Haemoscope in 2007, the acquisition of Infonale in July 2007, and, in 2009, Chico, California-based Altivation and Tucson, Arizona-based Sebra.
On August 21, 2007, 5D and IDM were officially merged into a new subsidiary called Haemonetics Software Solutions. The employees at both Edmonton (5D) and Rosemont (IDM) continue to work from their respective offices.
Further acquisitions included the April 2009 acquisition of Neoteric Technology Ltd and the April 2010 acquisition of California-based Global Med Technologies, Inc. Haemonetics acquired the Pall Corporation's transfusion medicine business on August 1, 2012 for ~$550 million.
In April 2024, it was announced Haemonetics had completed its acquisition of the Chicago-headquartered medical device temperature regulation manufacturer, Attune Medical for $160 million.
Product categories
Haemonetics products can be considered as belonging to two broad categories. Donor products (marketed to the blood donation industry, these include products that automate the blood donation process, automate the processing of blood, support pathogen inactivation and bacterial detection of blood, and test blood hematocrit); and products that are marketed to the surgical suite for blood loss management for patients. These products include surgical blood salvage (or "autotransfusion") devices, surgical field blood suction systems, and blood and patient warming systems.
Hemostasis
TEG 5000
Kaolin TEG
Kaolin TEG with Heparinase
RapidTEG
TEG Functional Fibrinogen
TEG PlateletMapping
TEG 6S
来源:维基百科 (英语), CC BY-SA 4.0 · 在维基百科上查看 ↗
HAE 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
HAE 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
10年表现 收入、净利润、利润率和每股收益趋势
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜?
盈利能力 毛利率、营业利润率和净利率;股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
财务健康 债务、流动性、偿付能力 — 资产负债表强度
成长 营收、每股收益 (EPS) 和净利润增长:同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
资本效率 资产周转率、库存周转率、应收账款周转率
HAE 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
- 强烈买入 5 33.3%
- 买入 6 40.0%
- 持有 4 26.7%
- 卖出 0 0.0%
- 强烈卖出 0 0.0%
12个月价格目标
10 位分析师 · 2026-08-13收益历史 每股收益实际值 vs 预估值,惊喜%,达标率,下次财报日期
| 期间 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|
| 2027年3月31日 | $1.14 | $1.09 | 0.05% |
| 2026年6月30日 | $1.14 | $1.09 | 0.05% |
| 2026年3月31日 | $1.29 | $1.28 | 0.01% |
| 2025年12月31日 | $1.31 | $1.26 | 0.05% |
| 2025年9月30日 | $1.27 | $1.12 | 0.15% |
| 2025年6月30日 | $1.10 | $1.03 | 0.07% |
| 2025年3月31日 | $1.24 | $1.23 | 0.01% |
同行比较(GICS 子行业) 关键指标与行业同行对比
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| HAE | $2.45B | 26.4 | -2.0% | 7.3% | 11.8% | 59.0% |
| COO | $13.70B | 37.4 | 5.1% | 9.2% | 4.6% | 65.5% |
| ALGN | $11.14B | 27.6 | 0.90% | 10.2% | 10.3% | 67.2% |
| LNTH | $4.30B | 19.5 | 0.50% | 15.2% | 20.7% | 61.1% |
| MMED | $3.71B | -10.2 | 14.2% | -10.7% | -9.3% | 54.2% |
| MMSI | $5.24B | 41.4 | 11.8% | 8.5% | 8.4% | 48.7% |
| ICUI | $3.52B | 4755.7 | -6.3% | 0.03% | 0.03% | 36.8% |
| QDEL | $1.99B | -1.8 | -1.9% | -41.4% | -48.0% | — |
| XRAY | $2.28B | -3.8 | -3.0% | -16.2% | -36.4% | 50.0% |
| NEOG | $1.95B | -224.2 | -2.7% | -0.91% | -0.38% | 46.9% |
| UFPT | $1.71B | 25.4 | 19.5% | 11.3% | 16.9% | 28.3% |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表 16
| 指标 | 趋势 | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.33B | $1.36B | $1.31B | $1.17B | $993M | $870M | $988M | $968M | $904M | $886M | $909M | $910M | |
| Cost of Revenue | $546M | $612M | $618M | $554M | $488M | $473M | $504M | $550M | $492M | $508M | $503M | $476M | |
| Gross Profit | $788M | $749M | $692M | $615M | $506M | $398M | $485M | $418M | $412M | $378M | $406M | $434M | |
| R&D Expense | $60M | $63M | $54M | $50M | $47M | $33M | $31M | $36M | $39M | $38M | $45M | $54M | |
| SG&A Expense | $442M | $437M | $430M | $377M | $340M | $275M | $282M | $273M | $317M | $302M | $317M | $337M | |
| Operating Expenses | $631M | $527M | $527M | $459M | $425M | $308M | $381M | $334M | $356M | $398M | $450M | $394M | |
| Operating Income | $157M | $222M | $165M | $156M | $81M | $90M | $103M | $84M | $56M | $-19M | $-44M | $41M | |
| Other Non-op | $-29M | $-10M | $-13M | $-15M | $-17M | $-17M | $-16M | $-10M | $-5M | $-8M | $-9M | $-9M | |
| Pretax Income | $128M | $212M | $152M | $141M | $64M | $73M | $87M | $74M | $60M | $-27M | $-53M | $31M | |
| Income Tax | $31M | $44M | $34M | $26M | $20M | $-7M | $11M | $19M | $14M | $-1M | $2M | $14M | |
| Net Income | $97M | $168M | $118M | $115M | $43M | $79M | $77M | $55M | $46M | $-26M | $-56M | $17M | |
| EPS (Basic) | $2.06 | $3.33 | $2.32 | $2.27 | $0.85 | $1.57 | $1.51 | $1.07 | $0.86 | $-0.51 | $-1.09 | $0.33 | |
| EPS (Diluted) | $2.05 | $3.31 | $2.29 | $2.24 | $0.84 | $1.55 | $1.48 | $1.04 | $0.85 | $-0.51 | $-1.09 | $0.32 | |
| Shares (Basic) | 47,179,000 | 50,330,000 | 50,706,000 | 50,783,000 | 51,047,000 | 50,688,000 | 50,692,000 | 51,533,000 | 52,755,000 | 51,524,000 | 50,910,000 | 51,533,000 | |
| Shares (Diluted) | 47,354,000 | 50,730,000 | 51,397,000 | 51,420,000 | 51,353,000 | 51,292,000 | 51,815,000 | 52,942,000 | 53,501,000 | 51,524,000 | 50,910,000 | 52,089,000 | |
| EBITDA | $157M | $222M | $165M | $156M | $81M | $90M | $103M | $84M | $56M | $-19M | $-44M | $41M |
资产负债表 25
| 指标 | 趋势 | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $245M | $307M | $179M | $284M | $259M | $192M | $137M | $169M | $180M | $140M | $115M | $161M | |
| Receivables | $217M | $203M | $207M | $179M | $159M | $128M | $165M | $185M | $151M | $153M | $157M | $146M | |
| Inventory | $306M | $365M | $317M | $259M | $293M | $323M | $270M | $194M | $161M | $177M | $187M | $211M | |
| Prepaid Expense | $66M | $60M | $66M | $47M | $44M | $51M | $31M | $27M | $29M | $41M | $29M | $40M | |
| Current Assets | $835M | $935M | $769M | $770M | $756M | $694M | $604M | $576M | $521M | $510M | $488M | $558M | |
| PP&E (Net) | $306M | $284M | $311M | $311M | $258M | $218M | $253M | $344M | $332M | $324M | $338M | $322M | |
| PP&E (Gross) | $842M | $837M | $959M | $944M | $869M | $817M | $832M | $933M | $873M | $807M | $786M | $732M | |
| Accum. Depreciation | $536M | $553M | $648M | $633M | $611M | $600M | $579M | $589M | $541M | $484M | $449M | $410M | |
| Goodwill | $656M | $604M | $565M | $466M | $467M | $466M | $211M | $211M | $211M | $211M | $268M | $334M | |
| Intangibles | $448M | $456M | $406M | $276M | $310M | $365M | $133M | $128M | $157M | $178M | $204M | $245M | |
| Other Non-current Assets | $142M | $164M | $136M | $107M | $63M | $71M | $62M | $12M | $12M | $12M | $14M | $11M | |
| Total Assets | $2.40B | $2.45B | $2.20B | $1.93B | $1.86B | $1.82B | $1.27B | $1.27B | $1.24B | $1.24B | $1.32B | $1.49B | |
| Accounts Payable | $51M | $67M | $73M | $64M | $58M | $50M | $51M | $63M | $55M | $43M | $40M | $48M | |
| Current Liabilities | $283M | $578M | $300M | $252M | $442M | $253M | $275M | $236M | $385M | $211M | $186M | $189M | |
| Capital Leases | $41M | $50M | $58M | $56M | $56M | $63M | $52M | · | · | · | · | · | |
| Deferred Tax | $38M | $63M | $63M | $36M | $29M | $44M | $11M | $20M | $7M | $12M | $21M | $33M | |
| Other Non-current Liabilities | $59M | $68M | $75M | $75M | $80M | $100M | $89M | $29M | $34M | $22M | $26M | $32M | |
| Long-term Debt | $1.24B | $1.22B | $808M | $766M | $774M | $708M | $382M | $350M | $254M | $316M | $408M | $430M | |
| Total Debt | $1.22B | $1.22B | $808M | $766M | $774M | $708M | $382M | $350M | $254M | $315M | $408M | $428M | |
| Common Stock | $453.0K | $482.0K | $508.0K | $504.0K | $511.0K | $509.0K | $503.0K | $510.0K | $523.0K | $523.0K | $509.0K | $517.0K | |
| Retained Earnings | $279M | $352M | $360M | $253M | $202M | $158M | $79M | $161M | $267M | $290M | $316M | $420M | |
| AOCI | $-38M | $-55M | $-36M | $-30M | $-26M | $-30M | $-45M | $-30M | $-19M | $-33M | $-35M | $-22M | |
| Stockholders' Equity | $796M | $821M | $960M | $818M | $749M | $732M | $587M | $668M | $752M | $740M | $722M | $826M | |
| Liabilities + Equity | $2.40B | $2.45B | $2.20B | $1.93B | $1.86B | $1.82B | $1.27B | $1.27B | $1.24B | $1.24B | $1.32B | $1.49B | |
| Shares Outstanding | 45,252,667 | 48,215,899 | 50,787,859 | 50,448,519 | 51,124,240 | 50,868,820 | 50,322,930 | 51,019,918 | 52,342,965 | 52,255,495 | 50,932,348 | 51,670,969 |
现金流 16
| 指标 | 趋势 | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $112M | $116M | $97M | $93M | $98M | $84M | $110M | $109M | $89M | $90M | $90M | $86M | |
| Stock-based Comp | $34M | $30M | $28M | $26M | $24M | $26M | $20M | $17M | $13M | $9M | $7M | $14M | |
| Deferred Tax | $-26M | $-6M | $-11M | $6M | $5M | $-21M | $-7M | $13M | $-6M | $-7M | $-1M | $4M | |
| Amort. of Intangibles | $50M | $56M | $41M | $42M | $57M | $41M | $34M | $25M | $32M | $37M | $59M | $34M | |
| Restructuring | $3M | $14M | $14M | $657.0K | $4M | $1M | $4M | $395.0K | $31M | $22M | $23M | $37M | |
| Operating Cash Flow | $293M | $182M | $182M | $273M | $172M | $109M | $158M | $159M | $220M | $160M | $122M | $127M | |
| CapEx | $33M | $39M | $38M | $191M | $97M | $37M | $49M | $119M | $75M | $76M | $102M | $122M | |
| Investing Cash Flow | $-180M | $-162M | $-322M | $-144M | $-86M | $-425M | $-57M | $-116M | $-63M | $-73M | $-105M | $-122M | |
| Debt Issued | · | · | · | · | · | · | $0 | $348M | $0 | $0 | · | $0 | |
| Net Debt Issued | · | $-5M | $-12M | $-10M | $-18M | $-22M | $-13M | $81M | $-62M | $-43M | $-21M | $-9M | |
| Stock Repurchased | $175M | $225M | $0 | $75M | $0 | $0 | $175M | $160M | $100M | $0 | $61M | $39M | |
| Net Stock Activity | $-175M | $-225M | $0 | $-75M | $0 | $0 | $-175M | $-160M | $-100M | $0 | $-61M | $-39M | |
| Financing Cash Flow | $-178M | $109M | $38M | $-100M | $-16M | $367M | $-131M | $-51M | $-121M | $-60M | $-63M | $-33M | |
| Net Change in Cash | $-61M | $128M | $-106M | $25M | $67M | $55M | $-32M | $-11M | $41M | $24M | $-46M | $-32M | |
| Taxes Paid | $61M | · | · | · | · | $12M | $12M | $8M | $9M | $7M | $8M | $11M | |
| Free Cash Flow | $260M | $142M | $115M | $163M | $76M | $72M | $109M | $40M | $146M | $84M | $19M | $5M |
盈利能力 8
| 指标 | 趋势 | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 59.0% | 55.0% | 52.8% | 52.6% | 50.9% | 45.7% | 49.0% | 43.1% | 45.6% | 42.7% | 44.7% | 47.7% | |
| Operating Margin | 11.8% | 16.3% | 12.6% | 13.4% | 8.1% | 10.3% | 10.5% | 8.6% | 6.2% | -2.2% | -4.8% | 4.5% | |
| Net Margin | 7.3% | 12.3% | 9.0% | 9.9% | 4.4% | 9.1% | 7.7% | 5.7% | 5.0% | -3.0% | -6.1% | 1.9% | |
| Pretax Margin | 9.6% | 15.6% | 11.6% | 12.1% | 6.4% | 8.4% | 8.8% | 7.6% | 6.6% | -3.1% | -5.9% | 3.4% | |
| EBITDA Margin | 11.8% | 16.3% | 12.6% | 13.4% | 8.1% | 10.3% | 10.5% | 8.6% | 6.2% | -2.2% | -4.8% | 4.5% | |
| ROA | 4.0% | 7.2% | 5.7% | 6.1% | 2.4% | 5.1% | 6.0% | 4.4% | 3.7% | -2.1% | -4.0% | 1.1% | |
| ROE | 11.8% | 19.4% | 12.3% | 14.5% | 5.9% | 11.0% | 13.2% | 8.7% | 6.1% | -3.6% | -7.2% | 2.0% | |
| ROIC | 5.9% | 8.6% | 7.2% | 8.0% | 3.6% | 6.8% | 9.4% | 6.1% | 4.3% | -1.8% | -4.0% | 1.8% |
流动性与偿付能力 4
| 指标 | 趋势 | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.0 | 1.6 | 2.6 | 3.1 | 1.7 | 2.7 | 2.2 | 2.4 | 1.4 | 2.4 | 2.6 | 3.0 | |
| Quick Ratio | 1.6 | 0.9 | 1.3 | 1.8 | 0.9 | 1.3 | 1.1 | 1.5 | 0.9 | 1.4 | 1.5 | 1.6 | |
| Debt / Equity | 1.5 | 1.5 | 0.8 | 0.9 | 1.0 | 1.0 | 0.7 | 0.5 | 0.3 | 0.4 | 0.6 | 0.5 | |
| LT Debt / Equity | 1.5 | 1.1 | 0.8 | 0.9 | 0.7 | 0.9 | 0.5 | 0.5 | 0.1 | 0.3 | 0.5 | 0.5 |
效率 3
| 指标 | 趋势 | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.6 | 0.6 | 0.6 | 0.6 | 0.5 | 0.6 | 0.8 | 0.8 | 0.7 | 0.7 | 0.6 | 0.6 | |
| Inventory Turnover | 1.6 | 1.8 | 2.1 | 2.0 | 1.6 | 1.6 | 2.2 | 3.1 | 2.9 | 2.8 | 2.5 | 2.3 | |
| Receivables Turnover | 6.4 | 6.7 | 6.8 | 6.9 | 6.9 | 5.9 | 5.6 | 5.8 | 5.9 | 5.7 | 6.0 | 5.9 |
增长率 9
| 指标 | 趋势 | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -2.0% | 4.0% | 12.0% | 17.7% | 14.1% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 4.5% | 11.1% | 14.6% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 8.9% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | -38.1% | 44.5% | 2.2% | 166.7% | -45.8% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | -2.9% | 58.0% | 13.9% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 5.8% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -42.0% | 42.6% | 1.9% | 166.1% | -45.4% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | -5.5% | 56.9% | 13.9% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 4.1% | · | · | · | · | · | · | · | · | · | · | · |
估值 (TTM) 14
| 指标 | 趋势 | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.33B | $1.36B | $1.31B | $1.17B | $993M | $870M | $988M | $968M | $904M | $886M | $909M | $910M | |
| Net Income TTM | $97M | $168M | $118M | $115M | $43M | $79M | $77M | $55M | $46M | $-26M | $-56M | $17M | |
| Market Cap | $2.45B | $3.05B | $4.33B | $4.17B | $3.26B | $5.70B | $5.08B | $4.46B | $3.83B | $2.12B | $1.80B | $2.28B | |
| Enterprise Value | $3.42B | $3.96B | $4.96B | $4.66B | $3.78B | $6.21B | $5.33B | $4.64B | $3.90B | $2.30B | $2.09B | $2.55B | |
| P/E | 26.4 | 19.1 | 37.3 | 36.9 | 76.0 | 72.3 | 68.2 | 84.1 | 86.1 | -79.5 | -32.4 | 138.2 | |
| P/S | 1.8 | 2.2 | 3.3 | 3.6 | 3.3 | 6.5 | 5.1 | 4.6 | 4.2 | 2.4 | 2.0 | 2.5 | |
| P/B | 3.1 | 3.7 | 4.5 | 5.1 | 4.4 | 7.8 | 8.7 | 6.7 | 5.1 | 2.9 | 2.5 | 2.8 | |
| P / Tangible Book | · | · | · | 54.9 | · | · | · | · | · | · | · | · | |
| P / Cash Flow | 8.3 | 16.8 | 23.8 | 15.3 | 18.9 | 52.4 | 32.1 | 28.0 | 17.4 | 13.3 | 14.7 | 18.0 | |
| P / FCF | 9.4 | 21.4 | 37.5 | 25.6 | 43.1 | 79.4 | 46.4 | 110.7 | 26.3 | 25.4 | 92.4 | 460.7 | |
| EV / EBITDA | 21.8 | 17.9 | 30.1 | 29.8 | 46.8 | 69.2 | 51.5 | 55.6 | 69.5 | -118.4 | -47.6 | 62.9 | |
| EV / FCF | 13.1 | 27.8 | 43.0 | 28.6 | 49.9 | 86.6 | 48.7 | 115.2 | 26.8 | 27.5 | 107.4 | 514.6 | |
| EV / Revenue | 2.6 | 2.9 | 3.8 | 4.0 | 3.8 | 7.1 | 5.4 | 4.8 | 4.3 | 2.6 | 2.3 | 2.8 | |
| Earnings Yield | 3.8% | 5.2% | 2.7% | 2.7% | 1.3% | 1.4% | 1.5% | 1.2% | 1.2% | -1.3% | -3.1% | 0.72% |
损益表 16
| 指标 | 趋势 | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $339M | $346M | $339M | $327M | $321M | $331M | $349M | $346M | $336M | $343M | $336M | $318M | $340M | $305M | $297M | |
| Cost of Revenue | $137M | $148M | $137M | $133M | $129M | $138M | $155M | $158M | $161M | $167M | $158M | $148M | $169M | $147M | $140M | |
| Gross Profit | $203M | $198M | $202M | $195M | $192M | $193M | $194M | $187M | $175M | $176M | $178M | $171M | $172M | $159M | $158M | |
| R&D Expense | $16M | $14M | $14M | $15M | $16M | $18M | $16M | $14M | $14M | $16M | $13M | $13M | $16M | $13M | $11M | |
| SG&A Expense | $119M | $121M | $109M | $102M | $111M | $115M | $106M | $107M | $108M | $109M | $112M | $115M | $98M | $95M | $92M | |
| Operating Expenses | $145M | $221M | $135M | $136M | $138M | $122M | $135M | $136M | $135M | $146M | $132M | $135M | $121M | $115M | $111M | |
| Operating Income | $57M | $-23M | $67M | $58M | $54M | $71M | $59M | $52M | $40M | $30M | $46M | $35M | $51M | $43M | $47M | |
| Other Non-op | $-10M | $-5M | $-7M | $-7M | $-9M | $-598.0K | $-9M | $-7M | $7M | $-7M | $-2M | $-2M | $-3M | $-1M | $-6M | |
| Pretax Income | $48M | $-28M | $60M | $51M | $45M | $71M | $50M | $45M | $47M | $23M | $44M | $33M | $48M | $42M | $41M | |
| Income Tax | $15M | $-8M | $15M | $13M | $11M | $13M | $12M | $11M | $8M | $3M | $13M | $8M | $5M | $9M | $8M | |
| Net Income | $33M | $-20M | $45M | $39M | $34M | $58M | $37M | $34M | $38M | $20M | $31M | $25M | $42M | $33M | $33M | |
| EPS (Basic) | $0.73 | $-0.42 | $0.96 | $0.81 | $0.71 | $1.17 | $0.75 | $0.66 | $0.75 | $0.40 | $0.62 | $0.49 | $0.84 | $0.65 | $0.65 | |
| EPS (Diluted) | $0.72 | $-0.41 | $0.95 | $0.81 | $0.70 | $1.17 | $0.74 | $0.66 | $0.74 | $0.40 | $0.61 | $0.48 | $0.84 | $0.64 | $0.64 | |
| Shares (Basic) | 45,361,000 | -95,314,000 | 46,792,000 | 47,590,000 | 48,111,000 | -101,797,000 | 50,286,000 | 50,898,000 | 50,943,000 | 27,000 | 50,768,000 | 50,727,000 | -102,174,000 | 50,509,000 | 50,953,000 | |
| Shares (Diluted) | 45,704,000 | -95,650,000 | 46,987,000 | 47,664,000 | 48,353,000 | -102,713,000 | 50,639,000 | 51,240,000 | 51,564,000 | 3,000 | 51,445,000 | 51,396,000 | -103,165,000 | 51,219,000 | 51,558,000 | |
| EBITDA | $57M | · | $67M | $58M | $54M | · | $59M | $52M | $40M | · | $46M | $35M | · | $43M | $47M |
资产负债表 25
| 指标 | 趋势 | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $223M | $245M | $363M | $296M | $293M | $307M | $321M | $299M | $344M | $179M | $194M | $351M | · | $224M | $241M | |
| Receivables | $216M | $217M | $196M | $207M | $201M | $203M | $212M | $214M | $201M | $207M | $212M | $174M | · | $181M | $172M | |
| Inventory | $307M | $306M | $321M | $336M | $361M | $365M | $360M | $382M | $374M | $317M | $304M | $286M | · | $256M | $255M | |
| Prepaid Expense | $65M | $66M | $63M | $60M | $59M | $60M | $113M | $61M | $59M | $66M | $55M | $55M | · | $45M | $48M | |
| Current Assets | $811M | $835M | $944M | $900M | $913M | $935M | $1.01B | $956M | $979M | $769M | $765M | $866M | · | $706M | $716M | |
| PP&E (Net) | $304M | $306M | $297M | $292M | $287M | $284M | $286M | $300M | $302M | $311M | $319M | $308M | · | $313M | $308M | |
| PP&E (Gross) | $854M | $842M | $837M | $815M | $795M | $837M | $867M | $939M | $949M | $959M | $979M | $950M | · | · | · | |
| Accum. Depreciation | $550M | $536M | $540M | $523M | $508M | $553M | $581M | $639M | $647M | $648M | $661M | $642M | · | · | · | |
| Goodwill | $657M | $656M | $607M | $606M | $607M | $604M | $605M | $616M | $613M | $565M | $555M | $465M | $466M | $466M | $465M | |
| Intangibles | $435M | $448M | $420M | $428M | $451M | $456M | $466M | $488M | $495M | $406M | $429M | $251M | · | $284M | $293M | |
| Other Non-current Assets | $150M | $142M | $216M | $208M | $196M | $164M | $160M | $156M | $142M | $136M | $127M | $117M | · | $103M | $80M | |
| Total Assets | $2.37B | $2.40B | $2.49B | $2.44B | $2.46B | $2.45B | $2.53B | $2.53B | $2.54B | $2.20B | $2.20B | $2.01B | · | $1.88B | $1.87B | |
| Accounts Payable | $56M | $51M | $49M | $62M | $46M | $67M | $63M | $69M | $77M | $73M | $57M | $80M | · | $64M | $61M | |
| Current Liabilities | $263M | $283M | $540M | $548M | $531M | $578M | $253M | $274M | $260M | $300M | $262M | $264M | · | $227M | $262M | |
| Capital Leases | · | $41M | · | · | · | $50M | · | · | · | $58M | · | · | · | · | · | |
| Deferred Tax | $39M | $38M | $56M | $58M | $59M | $63M | $61M | $63M | $65M | $63M | $62M | $35M | · | $40M | $36M | |
| Other Non-current Liabilities | $57M | $59M | $64M | $66M | $68M | $68M | $90M | $90M | $92M | $75M | $76M | $70M | · | $78M | $78M | |
| Long-term Debt | $1.19B | $1.24B | $1.22B | $1.22B | $1.22B | $1.25B | $1.22B | $1.22B | $1.22B | $808M | $871M | $762M | · | $767M | $818M | |
| Total Debt | $1.17B | · | $1.22B | $1.22B | $1.22B | · | $1.22B | $1.22B | $1.22B | · | $871M | $762M | · | $767M | $818M | |
| Common Stock | $455.0K | $453.0K | $468.0K | $467.0K | $482.0K | $482.0K | $502.0K | $504.0K | $512.0K | $508.0K | $508.0K | $507.0K | · | $504.0K | $506.0K | |
| Retained Earnings | $312M | $279M | $381M | $336M | $356M | $352M | $392M | $369M | $387M | $360M | $340M | $309M | · | $224M | $204M | |
| AOCI | $-42M | $-38M | $-35M | $-41M | $-36M | $-55M | $-56M | $-35M | $-43M | $-36M | $-24M | $-33M | · | $-36M | $-40M | |
| Stockholders' Equity | $837M | $796M | $911M | $849M | $882M | $821M | $907M | $879M | $905M | $960M | $943M | $894M | $818M | $776M | $729M | |
| Liabilities + Equity | $2.37B | $2.40B | $2.49B | $2.44B | $2.46B | $2.45B | $2.53B | $2.53B | $2.54B | $2.20B | $2.20B | $2.01B | · | $1.88B | $1.87B | |
| Shares Outstanding | 45,471,313 | 45,252,667 | 46,829,249 | 46,747,381 | 48,158,723 | 48,215,899 | 50,235,051 | 50,381,127 | 51,152,886 | 50,787,859 | 50,785,040 | 50,740,389 | · | 50,444,470 | 50,605,499 |
现金流 13
| 指标 | 趋势 | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $27M | $27M | $27M | $28M | $29M | $28M | $29M | $29M | $29M | $28M | $24M | · | $24M | $24M | · | |
| Stock-based Comp | $9M | $9M | $8M | $8M | $9M | $7M | $8M | $7M | $8M | $7M | $7M | · | $7M | $7M | · | |
| Deferred Tax | $668.0K | $-20M | $-2M | $-725.0K | $-3M | $3M | $-2M | $-2M | $-4M | $-6M | $-3M | · | · | · | · | |
| Amort. of Intangibles | $12M | $12M | $12M | $13M | $13M | $13M | $14M | $14M | $14M | $13M | $9M | $9M | $15M | $10M | $11M | |
| Restructuring | $2M | $196.0K | $1M | $204.0K | $1M | $984.0K | $4M | $5M | $5M | $6M | $8M | $86.0K | $701.0K | $44.0K | $165.0K | |
| Operating Cash Flow | $52M | $71M | $94M | $111M | $17M | $117M | $44M | $49M | $-27M | $64M | $-540.0K | · | $80M | $64M | · | |
| CapEx | $8M | $18M | $6M | $5M | $4M | $16M | $9M | $9M | $6M | $7M | $-3M | · | $93M | $17M | · | |
| Investing Cash Flow | $-22M | $-87M | $-29M | $-30M | $-33M | $18M | $-17M | $-23M | $-139M | $-13M | $-269M | · | $-18M | $-36M | · | |
| Net Debt Issued | $-2M | · | · | · | $-2M | · | · | · | $-2M | · | · | · | · | · | · | |
| Stock Repurchased | · | $100M | $0 | · | · | $150M | $0 | · | · | $0 | $0 | · | $0 | $0 | · | |
| Financing Cash Flow | $-52M | $-101M | $2M | $-77M | $-2M | $-151M | $1M | $-75M | $334M | $-64M | $109M | · | $-2M | $-50M | · | |
| Net Change in Cash | $-22M | $-118M | $67M | $4M | $-14M | $-14M | $22M | $-45M | $166M | $-15M | $-157M | · | $60M | $-17M | · | |
| Free Cash Flow | $44M | · | · | · | $14M | · | · | · | $-33M | · | · | · | · | · | · |
盈利能力 8
| 指标 | 趋势 | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 59.8% | · | 59.7% | 59.5% | 59.8% | · | 55.5% | 54.2% | 52.0% | · | 52.9% | 53.6% | · | 52.0% | 53.1% | |
| Operating Margin | 16.9% | · | 19.9% | 17.9% | 16.8% | · | 16.9% | 15.0% | 11.8% | · | 13.7% | 11.1% | · | 14.2% | 15.7% | |
| Net Margin | 9.7% | · | 13.2% | 11.8% | 10.6% | · | 10.8% | 9.8% | 11.4% | · | 9.3% | 7.8% | · | 10.8% | 11.2% | |
| Pretax Margin | 14.0% | · | 17.7% | 15.7% | 14.1% | · | 14.3% | 12.9% | 13.9% | · | 13.1% | 10.3% | · | 13.8% | 13.8% | |
| EBITDA Margin | 16.9% | · | 19.9% | 17.9% | 16.8% | · | 16.9% | 15.0% | 11.8% | · | 13.7% | 11.1% | · | 14.2% | 15.7% | |
| ROA | 1.4% | · | 1.8% | 1.6% | 1.4% | · | 1.6% | 1.5% | 1.7% | · | 1.5% | 1.3% | · | 1.8% | 1.8% | |
| ROE | 3.8% | · | 4.9% | 4.5% | 3.8% | · | 4.0% | 3.8% | 4.3% | · | 3.6% | 3.1% | · | 4.4% | 4.7% | |
| ROIC | 2.0% | · | 2.4% | 2.1% | 1.9% | · | 2.1% | 1.9% | 1.5% | · | 1.8% | 1.6% | · | 2.2% | 2.4% |
流动性与偿付能力 4
| 指标 | 趋势 | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.1 | · | 1.7 | 1.6 | 1.7 | · | 4.0 | 3.5 | 3.8 | · | 2.9 | 3.3 | · | 3.1 | 2.7 | |
| Quick Ratio | 1.7 | · | 1.0 | 0.9 | 0.9 | · | 2.1 | 1.9 | 2.1 | · | 1.5 | 2.0 | · | 1.8 | 1.6 | |
| Debt / Equity | 1.4 | · | 1.3 | 1.4 | 1.4 | · | 1.4 | 1.4 | 1.4 | · | 0.9 | 0.9 | · | 1.0 | 1.1 | |
| LT Debt / Equity | 1.4 | · | 1.0 | 1.1 | 1.0 | · | 1.3 | 1.4 | 1.3 | · | 0.9 | 0.8 | · | 1.0 | 1.0 |
效率 3
| 指标 | 趋势 | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.2 | 0.1 | · | 0.2 | 0.2 | · | 0.2 | 0.2 | |
| Inventory Turnover | 0.4 | · | 0.4 | 0.4 | 0.4 | · | 0.5 | 0.5 | 0.5 | · | 0.6 | 0.5 | · | 0.5 | 0.5 | |
| Receivables Turnover | 1.6 | · | 1.7 | 1.6 | 1.6 | · | 1.6 | 1.8 | 1.8 | · | 1.7 | 1.8 | · | 1.8 | 1.9 |
估值 (TTM) 14
| 指标 | 趋势 | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.33B | · | $1.34B | $1.34B | $1.35B | · | $1.37B | $1.34B | $1.30B | · | $1.27B | $1.23B | · | · | · | |
| Net Income TTM | $150M | · | $155M | $144M | $144M | · | $141M | $128M | $136M | · | $130M | $132M | · | · | · | |
| Market Cap | $3.51B | · | $3.76B | $2.25B | $3.55B | · | $3.90B | $4.02B | $4.23B | · | $4.34B | $4.55B | · | $3.97B | $3.75B | |
| Enterprise Value | $4.47B | · | $4.62B | $3.18B | $4.49B | · | $4.80B | $4.95B | $5.11B | · | $5.02B | $4.96B | · | $4.51B | $4.32B | |
| P/E | 24.3 | · | 25.1 | 16.6 | 26.0 | · | 28.2 | 32.0 | 31.5 | · | 33.8 | 35.0 | · | · | · | |
| P/S | 2.6 | · | 2.8 | 1.7 | 2.6 | · | 2.9 | 3.0 | 3.3 | · | 3.4 | 3.7 | · | · | · | |
| P/B | 4.2 | · | 4.1 | 2.7 | 4.0 | · | 4.3 | 4.6 | 4.7 | · | 4.6 | 5.1 | · | 5.1 | 5.1 | |
| P / Tangible Book | · | · | · | · | · | · | · | · | · | · | · | 25.6 | · | 155.7 | · | |
| P / Cash Flow | 67.2 | · | · | · | 204.3 | · | · | · | -154.3 | · | · | · | · | · | · | |
| P / FCF | 79.1 | · | · | · | 260.5 | · | · | · | -127.9 | · | · | · | · | · | · | |
| EV / EBITDA | 77.7 | · | 68.6 | 54.4 | 83.3 | · | 81.3 | 95.7 | 128.6 | · | 109.2 | 140.4 | · | 104.2 | 92.5 | |
| EV / FCF | 100.5 | · | · | · | 328.9 | · | · | · | -154.5 | · | · | · | · | · | · | |
| EV / Revenue | 3.4 | · | 3.5 | 2.4 | 3.3 | · | 3.5 | 3.7 | 3.9 | · | 3.9 | 4.0 | · | · | · | |
| Earnings Yield | 4.1% | · | 4.0% | 6.0% | 3.9% | · | 3.5% | 3.1% | 3.2% | · | 3.0% | 2.9% | · | · | · |
财务报表 损益表、资产负债表、现金流量表 — 年度,近5年
损益表
| 2026-03-28 | 2025-03-29 | 2024-03-30 | 2023-04-01 | 2022-04-02 | |
|---|---|---|---|---|---|
| 收入 | $1.33B | $1.36B | $1.31B | $1.17B | $993M |
| 毛利率 % | 59.0% | 55.0% | 52.8% | 52.6% | 50.9% |
| 营业利润率 % | 11.8% | 16.3% | 12.6% | 13.4% | 8.1% |
| 净收入 | $97M | $168M | $118M | $115M | $43M |
| 稀释后每股收益 (EPS) | $2.05 | $3.31 | $2.29 | $2.24 | $0.84 |
资产负债表
| 2026-03-28 | 2025-03-29 | 2024-03-30 | 2023-04-01 | 2022-04-02 | |
|---|---|---|---|---|---|
| 负债/股东权益比率 | 1.5 | 1.5 | 0.8 | 0.9 | 1.0 |
| 流动比率 | 3.0 | 1.6 | 2.6 | 3.1 | 1.7 |
| 速动比率 | 1.6 | 0.9 | 1.3 | 1.8 | 0.9 |
现金流
| 2026-03-28 | 2025-03-29 | 2024-03-30 | 2023-04-01 | 2022-04-02 | |
|---|---|---|---|---|---|
| 自由现金流 | $260M | $142M | $115M | $163M | $76M |
最新新闻 提及该公司的近期头条新闻
我的指标 您的个人关注列表 — 来自完整基本面的选定行
选择对您重要的指标 — 点击上方完整基本面中任意行的 ➕。
您的选择已保存,并会跟随您浏览所有股票。
机构持有人 (13F) 363 家申报者 · $2.6B 总计 · 截至 2026年6月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸;单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存,而非方向性判断。
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 62 (+3 与上一季度对比) | 43 (-12 与上一季度对比) | 108 (-5 与上一季度对比) | 112 (-3 与上一季度对比) | +1.2M |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天,外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过,优先显示最近一个已完整报告的季度对。
公司内部人士 72 位内幕人士 · 48 位高管 · 25 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Christopher Simon, | President & CEO | 2026年5月15日 A | 444704 | 0 | 0 | $0 |
| Brian Concannon | President & CEO | 2015年9月15日 M | 147040 | 0 | 0 | $0 |
| James Darecca | EVP, Chief Financial Officer | 2026年5月15日 A | 54444 | 0 | 0 | $0 |
| William P. Mr. Burke | EVP, Chief Financial Officer | 2021年8月23日 M | 30291 | 0 | 0 | $0 |
| Christopher J Lindop | CFO & EVP Business Development | 2016年1月13日 A | 56743 | 0 | 0 | $0 |
| Ronald J Ryan | VP and CFO | 2006年11月1日 P | 2101 | 0 | 0 | $0 |
| Stewart W Strong | President, Global Hospital | 2024年7月26日 S | 18196 | 0 | 0 | $0 |
| Byron Selman | President, Global Markets | 2016年10月25日 A | 23318 | 0 | 0 | $0 |
| Peter M Allen | President, Global Plasma | 2015年7月6日 M | 34102 | 0 | 0 | $0 |
| Kelly Michael P | President, Global Markets | 2013年11月11日 M | 10987 | 0 | 0 | $0 |
| Mikael Gordon | President, Global Markets | 2012年5月3日 M | 4442 | 0 | 0 | $0 |
| Remi Corlin | President, Asia | 2008年8月8日 M | 884 | 0 | 0 | $0 |
| Keiko Hattori | President, Haemonetics Japan | 2008年5月1日 P | 716 | 0 | 0 | $0 |
| Thomas Lawlor | President, Patient Division | 2007年11月28日 M | 0 | 0 | 0 | $0 |
| Ryoji Sakai | President, Japan | 2007年6月14日 M | 0 | 0 | 0 | $0 |
| Ulrich Eckert | President, Europe & Latin Am | 2006年11月1日 P | 890 | 0 | 0 | $0 |
| Yutaka Sakurada | President, Japan & Asia | 2005年5月2日 P | 2347 | 0 | 0 | $0 |
| Frank Chan | EVP, Chief Operating Officer | 2026年5月15日 A | 32936 | 0 | 0 | $0 |
| Kent J Davies | Chief Operating Officer | 2015年10月23日 S | 16891 | 0 | 0 | $0 |
| Farris Maryanne Maunsell | VP, Chief Accounting Officer | 2026年6月5日 F | 6242 | 0 | 0 | $0 |
| Laurie A. Miller | SVP, Human Resources | 2026年6月5日 F | 40987 | 0 | 0 | $0 |
| Roy Galvin | EVP, Chief Commercial Officer | 2026年5月15日 A | 39882 | 0 | 0 | $0 |
| Michelle L Basil | EVP and General Counsel | 2026年5月15日 A | 68829 | 0 | 0 | $0 |
| Anila Lingamneni | EVP, Chief Technology Officer | 2024年7月12日 S | 21331 | 0 | 0 | $0 |
| Josep Llorens | EVP, Global Manufacturing | 2024年5月28日 F | 30940 | 0 | 0 | $0 |
| Dan Goldstein | VP, Corporate Controller | 2022年6月13日 S | 4447 | 0 | 0 | $0 |
| Jacqueline Scanlan | SVP, Global Human Resources | 2021年6月7日 S | 4216 | 0 | 0 | $0 |
| Said Bolorforosh | EVP, Chief Technology Officer | 2019年11月11日 S | 1977 | 0 | 0 | $0 |
| Neil 122-62-507 Ryding | EVP, Global Manufacturing | 2018年6月7日 S | 15226 | 0 | 0 | $0 |
| David Fusco | EVP, Global Human Resources | 2016年10月25日 A | 16867 | 0 | 0 | $0 |
| Sandra Jesse | EVP and Chief Legal Officer | 2016年10月25日 A | 48166 | 0 | 0 | $0 |
| Jonathan White | Chief Science and Technology | 2015年10月26日 S | 30507 | 0 | 0 | $0 |
| Susan M Hanlon | VP Finance | 2015年10月26日 S | 20464 | 0 | 0 | $0 |
| Brian R Burns | EVP, Global QA/RA | 2015年10月23日 S | 16235 | 0 | 0 | $0 |
| Dave Helsel | EVP, Global Manufacturing | 2015年4月13日 D | 13216 | 0 | 0 | $0 |
| Kathleen Mcdaniel | EVP Global Human Resources | 2014年8月28日 S | 5013 | 0 | 0 | $0 |
| Warren Nighan JR | EVP, Global QA/RA | 2013年7月24日 A | 7618 | 0 | 0 | $0 |
| Joseph J Forish | VP, Human Resources | 2013年4月30日 P | 17279 | 0 | 0 | $0 |
| Phillip John Brancazio | VP, Global Manufacturing | 2011年5月4日 P | 3052 | 0 | 0 | $0 |
| Alicia R Lopez | VP, Corporate Affairs | 2011年4月5日 D | 2815 | 0 | 0 | $0 |
| Michael I Ruxin | VP Global Software Strategies | 2010年11月4日 P | 215 | 0 | 0 | $0 |
| Brad Nutter | Chairman of the Board | 2010年7月29日 A | 10580 | 0 | 0 | $0 |
| Robert B Ebbeling | Vice President, Operations | 2009年5月1日 P | 15849 | 0 | 0 | $0 |
| Jan Conneely | VP & GM, Arryx, Inc. | 2008年5月1日 P | 1041 | 0 | 0 | $0 |
| William Granville | VP, Manufacturing | 2008年5月1日 P | 12188 | 0 | 0 | $0 |
| Mark A Popovsky | VP, Corporate Medical Director | 2008年5月1日 P | 4891 | 0 | 0 | $0 |
| Stephen Swenson | VP & General Mgr, Global Plasm | 2008年5月1日 P | 3024 | 0 | 0 | $0 |
| William Roche Still | VP & Gen Mrg, Therapeutics Bus | 2007年5月4日 M | 4193 | 0 | 0 | $0 |
| Lloyd Emerson Johnson | 董事 | 2026年7月24日 A | 15471 | 0 | 0 | $0 |
| Diane M Bryant | 董事 | 2026年7月24日 A | 9664 | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士;净额=仅公开市场买卖
激进投资者及 5%+ 股东 8 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权,意图影响发行人(激进股东持股、董事会活动、并购)。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| 未披露的报告人, 未披露的报告人, 未披露的报告人, 未披露的报告人 | 2004年2月6日 | — | 初始申报 | — | SEC |
| 未披露的报告人, 未披露的报告人, 未披露的报告人, 未披露的报告人 | 2003年8月20日 | — | 初始申报 | — | SEC |
| 未披露的报告人, 未披露的报告人, 未披露的报告人, 未披露的报告人 | 2003年8月8日 | — | 初始申报 | — | SEC |
| 未披露的报告人, 未披露的报告人, 未披露的报告人, 未披露的报告人 | 2003年6月24日 | — | 初始申报 | — | SEC |
| 未披露的报告人, 未披露的报告人, 未披露的报告人, 未披露的报告人 | 2003年6月19日 | — | 初始申报 | — | SEC |
| 未披露的报告人, 未披露的报告人, 未披露的报告人, 未披露的报告人 | 2003年6月3日 | — | 初始申报 | — | SEC |
| 未披露的报告人, 未披露的报告人, 未披露的报告人, 未披露的报告人 | 2003年5月27日 | — | 初始申报 | — | SEC |
| 未披露的报告人, 未披露的报告人, 未披露的报告人, 未披露的报告人 | 2001年6月15日 | — | 初始申报 | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF持仓 由 88 只交易所交易基金持有
权重仅反映直接股权持仓(N-PORT);杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
| 基金 | 权重 | 单位 | 截至 | 来源 |
|---|---|---|---|---|
| NBSM · Neuberger Berman ETF Trust | 1.86% | 61981 NS | 2026年5月31日 | N-PORT |
| JSML · Janus Detroit Street Trust | 0.84% | 43927 NS | 2026年4月30日 | N-PORT |
| JSMD · Janus Detroit Street Trust | 0.77% | 125093 NS | 2026年4月30日 | N-PORT |
| ROSC · Lattice Strategies Trust | 0.64% | 5836 NS | 2026年4月30日 | N-PORT |
| SIXL · EXCHANGE TRADED CONCEPTS TRUST | 0.46% | 12701 NS | 2026年5月31日 | N-PORT |
| PSC · Principal Exchange-Traded Funds | 0.36% | 110180 NS | 2026年6月30日 | N-PORT |
| CALF · Pacer Funds Trust | 0.35% | 201070 NS | 2026年4月30日 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0.32% | 35814 NS | 2026年5月31日 | N-PORT |
| ABCS · EA Series Trust | 0.31% | 522 NS | 2026年5月29日 | N-PORT |
| FYC · First Trust Exchange-Traded Alpha... | 0.24% | 41437 NS | 2026年4月30日 | N-PORT |
| AVSC · AMERICAN CENTURY ETF TRUST | 0.19% | 76694 NS | 2026年5月31日 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund ... | 0.14% | 17393 NS | 2026年4月30日 | N-PORT |
| MIDE · DBX ETF Trust | 0.13% | 63 NS | 2026年5月29日 | N-PORT |
| BKSE · BNY Mellon ETF Trust | 0.13% | 1703 NS | 2026年4月30日 | N-PORT |
| JPSE · J.P. Morgan Exchange-Traded Fund ... | 0.12% | 12097 NS | 2026年4月30日 | N-PORT |
| SMDX · Tidal Trust III | 0.12% | 2419 NS | 2026年4月30日 | N-PORT |
| NUSC · Nushares ETF Trust | 0.11% | 23551 NS | 2026年4月30日 | N-PORT |
| FSMD · FIDELITY COVINGTON TRUST | 0.11% | 42163 NS | 2026年4月30日 | N-PORT |
| FNDA · SCHWAB STRATEGIC TRUST | 0.10% | 126817 NS | 2026年5月31日 | N-PORT |
| EBIT · Harbor ETF Trust | 0.09% | 168 NS | 2026年4月30日 | N-PORT |
| RSSL · Global X Funds | 0.09% | 20324 NS | 2026年4月30日 | N-PORT |
| ITWO · ProShares Trust | 0.08% | 2210 NS | 2026年5月31日 | N-PORT |
| PTMC · Pacer Funds Trust | 0.08% | 5212 NS | 2026年4月30日 | N-PORT |
| DFAS · Dimensional ETF Trust | 0.07% | 159737 NS | 2026年4月30日 | N-PORT |
| MVV · ProShares Trust | 0.07% | 1606 NS | 2026年5月31日 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0.07% | 222776 NS | 2026年5月31日 | N-PORT |
| FYX · First Trust Exchange-Traded Alpha... | 0.06% | 12283 NS | 2026年4月30日 | N-PORT |
| MIDU · Direxion Shares ETF Trust | 0.06% | 770 NS | 2026年4月30日 | N-PORT |
| FSCC · Federated Hermes ETF Trust | 0.05% | 2220 NS | 2026年5月31日 | N-PORT |
| AVUQ · AMERICAN CENTURY ETF TRUST | 0.05% | 1979 NS | 2026年5月31日 | N-PORT |
| FAD · First Trust Exchange-Traded Alpha... | 0.05% | 3866 NS | 2026年4月30日 | N-PORT |
| UMDD · ProShares Trust | 0.05% | 224 NS | 2026年5月31日 | N-PORT |
| UWM · ProShares Trust | 0.05% | 1729 NS | 2026年5月31日 | N-PORT |
| DFAT · Dimensional ETF Trust | 0.05% | 105201 NS | 2026年4月30日 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0.05% | 21461 NS | 2026年4月30日 | N-PORT |
| GSSC · Goldman Sachs ETF Trust | 0.04% | 5317 NS | 2026年5月31日 | N-PORT |
| URTY · ProShares Trust | 0.03% | 1750 NS | 2026年5月31日 | N-PORT |
| AVSU · AMERICAN CENTURY ETF TRUST | 0.03% | 2270 NS | 2026年5月31日 | N-PORT |
| EBI · RBB Fund Trust | 0.03% | 2598 NS | 2026年5月31日 | N-PORT |
| TILT · FlexShares Trust | 0.03% | 8470 NS | 2026年4月30日 | N-PORT |
| AVUS · AMERICAN CENTURY ETF TRUST | 0.02% | 44580 NS | 2026年5月31日 | N-PORT |
| DXUV · Dimensional ETF Trust | 0.02% | 1323 NS | 2026年4月30日 | N-PORT |
| DFUV · Dimensional ETF Trust | 0.02% | 40040 NS | 2026年4月30日 | N-PORT |
| HDG · ProShares Trust | 0.01% | 44 NS | 2026年5月31日 | N-PORT |
| DCOR · Dimensional ETF Trust | 0.01% | 6668 NS | 2026年4月30日 | N-PORT |
| DFAC · Dimensional ETF Trust | 0.01% | 97492 NS | 2026年4月30日 | N-PORT |
| DFSU · Dimensional ETF Trust | 0.01% | 2539 NS | 2026年4月30日 | N-PORT |
| FNDB · SCHWAB STRATEGIC TRUST | 0.01% | 1282 NS | 2026年5月31日 | N-PORT |
| DFAU · Dimensional ETF Trust | 0.01% | 11534 NS | 2026年4月30日 | N-PORT |
| DFUS · Dimensional ETF Trust | 0.00% | 14005 NS | 2026年4月30日 | N-PORT |